Overview of Biotechnology in Health Care

Abstract

Get full access to this article

View all access options for this article.

References

Van Noordwijk J : Quality assurance of products manufactured by recombinant DNA technology. Arzneim-Forsch Drug Res 38:943-947,1988

Anon : Commercial biotechnology: An international analysis. Washington, DC, Office of Technology Assessment, OTA-BA-218,1984

Pharmaceutical Manufacturers Association : Biotechnology Medicines. Washington, DC, 1990

Collen D. , Lijnen HR , Rodd PA , et al: Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 38:346-388, 1989

Crabbe SJ , Cloninger CC : Tissue plasminogen activator: A new thrombolytic agent. Clin Pharm 6:373-386, 1987

DeWood MA , Spores J. , Motske R. , et al: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897-902, 1980

Gruppo Italiano perlo Studio della Streptochinasi nell'Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction . Lancet 1:397-401, 1986

ISIS-2 Collaborative Group : Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1:349-360, 1988

AIMS Trial Study Group : Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet 1:545-549, 1988

10.

Hoylaerts M. , Rijken DC , Lijnen HR , et al: Kinetics of the activation of plasminogen by human tissue plasminogen activator: Role of fibrin. J Biol Chem 257:2912-2919, 1982

11.

Romson JL , Hook BG , Kunkel SL , et al: Reduction of the extent of ischaemic myocardial injury by neutrophil depletion in the dog. Circulation 67:1016-1027, 1985

12.

McCord J. : Oxygen-derived free radicals in post-ischemic tissue injury. N Engl J Med 312:159-163,1985

13.

Ferrari R. , Ceconi C. , Curello S. , et al: Superoxide dismutase: Possible therapeutic use in cardiovascular disease. Pharmacol Res 21:57-65,1989 (suppl 2)

14.

Ferrari R. , Ceceoni C. , Curello S. , et al: Intracellular effects of myocardial ischaemia and reperfusion: Role of calcium and oxygen. Eur Heart J 7:2-12, 1986

15.

Ambrosio G. , Weisfeld ML , Jacobys WE , et al: Evidence for a reversible oxygen radical mediated component of reperfusion injury: Reduction by recombinant human superoxide dismutase administered at the time of reflow . Circulation 75:282-291, 1987

16.

Shlafer M, Kane Pf, Kirsh MM: Superoxide dismutase plus catalase enhances efficacy of hypothermic cardioplegic to protect the globally ischaemic, reperfused heart. J Thorac Cardiovasc Surg 83:830-839, 1982

17.

Burton KP : Superoxide dismutase enhances recovery following myocardial ischaemia . Am J Physiol 248:H637-643,1985

18.

Myers CL , Weiss SJ , Kirsh MM , et al: Effects of supplementing hypothermic crystalloid cardioplegic solution with catalase, superoxide dismutase, allopurinol, or deferoxamine on function recovery of globally ischemic and reperfused isolated hearts. J Thorac Cardiovasc Surg 91:281-289, 1986

19.

Jolly SR , Kane WJ , Baile MB , et al: Canine myocardial reperfusion injury: Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 54:277-285, 1984

20.

Hatori N. , Miyazaki A. , Drury JL , et al: Beneficial effect of coronary venous retroinfusion of superoxide dismutase and catalase on reperfusion arrhythmias, myocardial function and infarct size in dogs. J Cardiovasc Pharmacol 14:396-404, 1989

21.

Molina P. , Downey JM : Oxyradical mediated injury occurs on reperfusion of ischemic rabbit heart . Fed Proc 46:831, 1987

22.

Gallagher KP , Buda AJ , Pace D. , et al: Failure of superoxide dismutase and catalase to alter size of infarction in conscious dogs after three hours of occlusion followed by reperfusion. Circulation 73:1065-1076, 1986

23.

Najima J. , Canfield DR , Manders WT , et al: Failure of superoxide dismutase and catalase to alter size of infarct and functional recovery in conscious dogs with reperfusion. Circulation 76:IV-198, 1987

24.

Hammond B. , Kontos HA , Hess ML : Oxygen radicals in the adult respiratory distress syndrome, in myocardial ischemia and reperfusion injury, and in cerebral vascular damage. Can J Physiol Pharmacol 63:173-187, 1985

25.

Antonarakis SE , Youssoufian H. , Kazazian HH : Molecular genetics of hemophilia A in man (factor VIII deficiency). Mol Biol Med 4:81-94, 1987

26.

Wood WI , Capon DJ , Simonsen CC , et al: Expression of active human factor VIII from recombinant DNA clones. Nature 312:330-337, 1984

27.

Toole JJ , Knopf JL , Woxnay JM , et al: Molecular cloning of a cDNA encoding human antihaemophilic factor . Nature 312:342-347, 1984

28.

White GC , McMillan CW , Kingdon HS , et al: Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 320:166-170, 1989

29.

Schwartz RS , Abildaard CF , Aledort LM , et at: Human recombinant DNA-derived antihemophilic factor (Factor VIII) in the treatment of hemophilia A. N Engl J Med 323:1800-1805, 1990

30.

Faulds D. , Sorkin EM : Epoetin (Recombinant human erythropoietin). Drugs 38:863-899, 1989

31.

Sobota JT : Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. U.S. multicenter trials. Contrib Nephrol 76:166-178, 1989

32.

Eschbach JW , Abdulhadi MH , Browne JK , et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 111:992-1000, 1989

33.

Nielsen OJ , Thaysen JH : Response to erythropoietin in anaemic haemodialysis patients. J Intern Med 226:89-94, 1989

34.

Bommer J. , Kugel M. , Schoppe W. , et al: Dose-related effects of recombinant human erythropoietin on erythropoiesis: Results of a multicenter trial in patients with end-stage renal disease. Contrib Nephrol 66:85-93, 1988

35.

Eschbach JW , Egrie JC , Downing MR , et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of combined phase I and II clinical trials. N Engl J Med 316:73-78, 1987

36.

Eschbach JW , Kelly MR , Haley R. , et al: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin . N Engl J Med 321:158-163,1989

37.

Casati S. , Passerini P. , Campise MR , et al: Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having hemodialysis. Br Med J 295:1017-1020,1987

38.

Schaefer RM , Kuerner B. , Zech M. , et al: Treatment of the anemia of hemodialysis with recombinant human erythropoietin. Int J Artif Organs 11:249-254, 1988

39.

Ahrens ER , Gossain W. , Rovner DR : Human insulin: Its development and clinical use. Postgrad Med 80:181-187, 1986

40.

Pickup JC , Bilous RW , Viberti C. , et al: Plasma insulin and C-peptide after subcutaneous and intravenous administration of human insulin (recombinant DNA) and purified porcine insulin in healthy men. Diabetes Care 5:29-34, 1982 (suppl 2)

41.

Clark AJ , Wiles PG , Leiper JM , et al: A double-blind crossover trial comparing human insulin (recombinant DNA) with animal insulins in the treatment of previously insulin-treated diabetic patients. Diabetes Care 5:129-134, 1982 (suppl 2)

42.

Fineberg SE , Galloway JA , Fineberg NA , et al: Immunogenicity of recombinant DNA human insulin. Diabetologia 25:465-469, 1983

43.

The MJ : Human insulin: DNA technology's first drug. Am J Hosp Pharm 46:S9-S11, 1989 (suppl 2)

44.

Valenta LJ , Elias AN : Insulin-induced lipodystrophy in diabetic patients resolved by treatment with human insulin. Ann Intern Med 102:790-791, 1985

45.

Kaplan SL : Clinical studies with recombinant-DNA derived methionyl human growth hormone in growth deficient children. Lancet 1:697-700, 1986

46.

Thorner M. , Vance ML : Growth hormone, 1988. J Clin Invest 82:745-777, 1988

47.

Salomon F. , Cuneo RC , Hesp R. , et al: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency . N Engl J Med 321:1797-1803,1989

48.

Conference. Growth and growth disorders. Acta Paediatr Scand 343:3-246,1988 (suppl)

49.

Council on Scientific Affairs : Drug abuse in athletes. JAMA 259:1703-1705, 1988

50.

Sporn MB , Roberts AB : Peptide growth factors and inflammation, tissue repair, and cancer . J Clin Invest 78:329-332, 1986

51.

Brown GL , Curstinger L. , Brightwell JR , et al: Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J Exp Med 163:1319-1324, 1986

52.

Brown GL , Curstinger LJ , White M. , et al: Acceleration of tensile strength of incisions treated with EGF and TGF-B. Ann Surg 208:788-794,1988

53.

Brown GL , Nanney LB , Griffen J. , et al: Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 321:76-79, 1989

54.

Hadden JW : Correction of secondary T-cell immunodeficiencies with biological substances and drugs. Cancer Detect Prev 1:409-421, 1987 (suppl)

55.

Iizawa Y. , Nakao M. , Kondo M. : Protective effect of recombinant human interleukin-2 against lethal infection caused by Klebsiella pneumoniae. Microbiol Immunol 34: 185-195,1990

56.

Gutierrez-Ramos JC , Andreu JL , Reville Y. , et al: Recovery from autoimmunity of MRL/Ipr mice after infection with an interieukin-2/vaccinia recombinant virus. Nature 346:271-274, 1990

57.

Winkelhake JL , Gauny SS : Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol Rev 42:1-28, 1990